Gout News

A 64-year-old man presented to the emergency department with a 3-day history of swelling of the left knee. He has had hypertension for the past 8 years, and has been taking telmisartan 40 mg once daily and hydrochlorothiazide 12.5 mg once daily.

WASHINGTON — At the American College of Rheumatology Annual Meeting, Robert Terkeltaub, MD, in the division of rheumatology at the VA Medical Center in San Diego, California, reviewed his pooled safety study from the phase 3 program of lesinurad in gout in which there was an increase in safety signal.

WASHINGTON — At the American College of Rheumatology Annual Meeting, Kenneth G. Saag, MD, professor of medicine in the Division of Clinical Immunology and Rheumatology at the University of Alabama at Birmingham, discussed the CLEAR 1 and 2 extension studies of lesinurad and allopurinol combination therapy in patients with gout.

WASHINGTON — No association was reported between allopurinol use and renal dysfunction, according to a presentation at the American College of Rheumatology Annual Meeting.

WASHINGTON — At the American College of Rheumatology Annual Meeting, Leonard H. Calabrese, DO, rheumatologist at the Cleveland Clinic and Chief Medical Editor of Healio Rheumatology, discussed two discoveries for the treatment of gout.

WASHINGTON — Allopurinol prescription was not associated with an increased risk for deterioration of renal function, according to data presented at the American College of Rheumatology Annual Meeting.

WASHINGTON — Allopurinol prescription was not associated with an increased risk for deterioration of renal function, according to data presented at the American College of Rheumatology Annual Meeting.

WASHINGTON — Reaching target serum uric acid levels with urate-lowering therapy in chronic kidney disease was associated with improvement in the estimated glomerular filtration rate, according to findings presented at the American College of Rheumatology Annual Meeting.

The American College of Physicians released recommendations for the diagnosis and management of gout which omitted the 6-mg/dL treat-to-target approach that was recommended by the American College of Rheumatology in 2012, according to recently published reports. Instead, the physician group recommend practitioners wait for repeated attacks before the initiation of urate-lowering therapy.

The ACP recently released evidence-based clinical practice guidelines for managing and diagnosing acute gout, published in Annals of Internal Medicine.